Cathie Wood
CRSP icon

Cathie Wood’s CRISPR Therapeutics CRSP Stock Holding History

Cathie Wood’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-1,300
Closed -$85K – 235
2022
Q3 		$85K Hold
1,300
– – ﹤0.01% 238
2022
Q2 		$75K Hold
1,300
– – ﹤0.01% 339
2022
Q1 		$82K Hold
1,300
– – ﹤0.01% 344
2021
Q4 		$99K Buy
+1,300
New +$114K ﹤0.01% 355

Other funds holding CRSP

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
GP
GSK plc London $602M AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Cathie Wood's CRSP Position: Q2 2026 in Review

Cathie Wood reduced its CRISPR Therapeutics (CRSP) stake by 16% in Q2 2026, selling an estimated $97.7M and leaving 9,460,939 shares worth $516M. The position accounts for 3.35% of the portfolio, ranked #6.

Cathie Wood first reported a position in CRSP in Q2 2017 and has held it in 37 quarters since. The position peaked at $1.59B in Q4 2020. 520 funds tracked by Wall St. Rank hold CRSP as of Q2 2026.

  • Cathie Wood held 9,460,939 shares of CRISPR Therapeutics worth $516M as of Q2 2026.
  • Cathie Wood sold 1,852,684 CRISPR Therapeutics shares in Q2 2026, an estimated $97.7M.
  • CRISPR Therapeutics made up 3.35% of Cathie Wood's portfolio in Q2 2026, its #6 holding.
  • Cathie Wood first reported a position in CRISPR Therapeutics in Q2 2017 and has held it in 37 quarters since.
  • Cathie Wood's CRISPR Therapeutics position peaked at $1.59B in Q4 2020.
  • 520 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q2 2026.

Based on ARK Investment Management's 13F filing for Q2 2026, filed 14 Aug 2026.